Ehl S, Aichele P, Ramseier H, Barchet W, Hombach J, Pircher H, Hengartner H, Zinkernagel R M
Institute of Experimental Immunology, Department of Pathology, University of Zürich.
Nat Med. 1998 Sep;4(9):1015-9. doi: 10.1038/2001.
We studied antigen-specific T-cell tolerization therapy using skin transplantation across a defined minor histocompatibility antigen difference. Specific tolerization protocols using short-lived peptide or long-lived spleen cells presenting the peptide as antigen prevented graft rejection without immunosuppression when started before or as long as 10 days after transplantation. Peptide-induced T-cell tolerance was transient, and antigen presentation by the graft was not sufficient to maintain tolerance. In contrast, transfer of antigen-expressing lymphoid cells induced long-lasting tolerance correlating with donor cell chimerism. These findings show that antigen-specific tolerization can induce graft acceptance even when begun after transplantation and that long-term graft survival depends on persistence of the tolerizing antigen.
我们利用跨越明确的次要组织相容性抗原差异的皮肤移植来研究抗原特异性T细胞耐受疗法。当在移植前或移植后长达10天开始使用呈递该肽作为抗原的短寿命肽或长寿命脾细胞的特异性耐受方案时,可在无免疫抑制的情况下防止移植物排斥。肽诱导的T细胞耐受是短暂的,且移植物的抗原呈递不足以维持耐受。相比之下,表达抗原的淋巴细胞的转移诱导了与供体细胞嵌合相关的持久耐受。这些发现表明,即使在移植后开始,抗原特异性耐受也可诱导移植物接受,且长期移植物存活取决于耐受抗原的持续存在。